FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4214653742> ?p ?o ?g. }

• W4214653742 endingPage "992" @default.
• W4214653742 startingPage "987" @default.
• W4214653742 abstract "Background/aim To assess the long-term safety and efficacy of epimacular brachytherapy (EMB) for chronic, active, neovascular age-related macular degeneration (nAMD). Methods This pivotal, randomised, controlled surgical device trial recruited patients with chronic nAMD receiving intravitreal ranibizumab from 24 UK hospitals. Participants were randomised to either pars plana vitrectomy with 24 Gray EMB and pro re nata (PRN) ranibizumab (n=224) or PRN ranibizumab monotherapy (n=119). Although masking was not possible, masked clinicians assessed best-corrected visual acuity (BCVA) and imaging. After month 24, participants reverted to standard care, with either ranibizumab or aflibercept, returning for a month 36 study visit. Results Of 363 participants, 309 (85.1%) completed month 36. The number of injections was 12.1±8.1 in the EMB group versus 11.4±6.1 in the ranibizumab group (difference 0.7, 95% CI of difference −0.9 to 2.3, p = 0.41) between months 1 and 36, and 3.6±3.3 (n=200) versus 3.9±2.7 (n=102) (difference −0.3, 95% CI of difference −1.0 to 0.4, p=0.43) between months 25 and 36 (standard care). Over 36 months, BCVA change was −19.7±18.5 letters in the EMB group and −4.8±12.5 in the ranibizumab group (difference −14.9, 95% CI of difference −18.5 to −11.2, p < 0.0001). The month 36 BCVA of 20 EMB-treated participants with microvascular abnormalities (MVAs) at month 24 was similar to EMB-treated participants without MVAs (−21.8 vs −19.4 letters, p = 0.65). Conclusion EMB does not reduce the number of anti-vascular endothelial growth factor (VEGF) injections, either within or outside of a trial setting, and is associated with worse BCVA than anti-VEGF monotherapy. Trial registration number NCT01006538 ." @default.
• W4214653742 created "2022-03-02" @default.
• W4214653742 creator A5007082429 @default.
• W4214653742 creator A5008260799 @default.
• W4214653742 creator A5017540407 @default.
• W4214653742 creator A5018227698 @default.
• W4214653742 creator A5019521414 @default.
• W4214653742 creator A5019920784 @default.
• W4214653742 creator A5036636918 @default.
• W4214653742 creator A5051978807 @default.
• W4214653742 creator A5055401260 @default.
• W4214653742 creator A5070533172 @default.
• W4214653742 creator A5074372735 @default.
• W4214653742 creator A5088229706 @default.
• W4214653742 creator A5088900128 @default.
• W4214653742 creator A5082186634 @default.
• W4214653742 date "2022-02-25" @default.
• W4214653742 modified "2023-10-14" @default.
• W4214653742 title "Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial" @default.
• W4214653742 cites W1968495851 @default.
• W4214653742 cites W1969912452 @default.
• W4214653742 cites W1984941380 @default.
• W4214653742 cites W2023577181 @default.
• W4214653742 cites W2033711787 @default.
• W4214653742 cites W2055797705 @default.
• W4214653742 cites W2076373083 @default.
• W4214653742 cites W2079049784 @default.
• W4214653742 cites W2082572493 @default.
• W4214653742 cites W2082605046 @default.
• W4214653742 cites W2092934856 @default.
• W4214653742 cites W2102029073 @default.
• W4214653742 cites W2331554243 @default.
• W4214653742 cites W2331755526 @default.
• W4214653742 cites W2336464624 @default.
• W4214653742 cites W2626835548 @default.
• W4214653742 cites W3041211928 @default.
• W4214653742 cites W4292528167 @default.
• W4214653742 doi "https://doi.org/10.1136/bjophthalmol-2021-320620" @default.
• W4214653742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35217515" @default.
• W4214653742 hasPublicationYear "2022" @default.
• W4214653742 type Work @default.
• W4214653742 citedByCount "0" @default.
• W4214653742 crossrefType "journal-article" @default.
• W4214653742 hasAuthorship W4214653742A5007082429 @default.
• W4214653742 hasAuthorship W4214653742A5008260799 @default.
• W4214653742 hasAuthorship W4214653742A5017540407 @default.
• W4214653742 hasAuthorship W4214653742A5018227698 @default.
• W4214653742 hasAuthorship W4214653742A5019521414 @default.
• W4214653742 hasAuthorship W4214653742A5019920784 @default.
• W4214653742 hasAuthorship W4214653742A5036636918 @default.
• W4214653742 hasAuthorship W4214653742A5051978807 @default.
• W4214653742 hasAuthorship W4214653742A5055401260 @default.
• W4214653742 hasAuthorship W4214653742A5070533172 @default.
• W4214653742 hasAuthorship W4214653742A5074372735 @default.
• W4214653742 hasAuthorship W4214653742A5082186634 @default.
• W4214653742 hasAuthorship W4214653742A5088229706 @default.
• W4214653742 hasAuthorship W4214653742A5088900128 @default.
• W4214653742 hasConcept C118487528 @default.
• W4214653742 hasConcept C126322002 @default.
• W4214653742 hasConcept C141071460 @default.
• W4214653742 hasConcept C168563851 @default.
• W4214653742 hasConcept C2776403814 @default.
• W4214653742 hasConcept C2776694085 @default.
• W4214653742 hasConcept C2777063560 @default.
• W4214653742 hasConcept C2777802072 @default.
• W4214653742 hasConcept C2778257484 @default.
• W4214653742 hasConcept C2778749236 @default.
• W4214653742 hasConcept C2780699112 @default.
• W4214653742 hasConcept C2781100027 @default.
• W4214653742 hasConcept C2781148688 @default.
• W4214653742 hasConcept C2781242345 @default.
• W4214653742 hasConcept C2781359195 @default.
• W4214653742 hasConcept C3018023364 @default.
• W4214653742 hasConcept C71924100 @default.
• W4214653742 hasConceptScore W4214653742C118487528 @default.
• W4214653742 hasConceptScore W4214653742C126322002 @default.
• W4214653742 hasConceptScore W4214653742C141071460 @default.
• W4214653742 hasConceptScore W4214653742C168563851 @default.
• W4214653742 hasConceptScore W4214653742C2776403814 @default.
• W4214653742 hasConceptScore W4214653742C2776694085 @default.
• W4214653742 hasConceptScore W4214653742C2777063560 @default.
• W4214653742 hasConceptScore W4214653742C2777802072 @default.
• W4214653742 hasConceptScore W4214653742C2778257484 @default.
• W4214653742 hasConceptScore W4214653742C2778749236 @default.
• W4214653742 hasConceptScore W4214653742C2780699112 @default.
• W4214653742 hasConceptScore W4214653742C2781100027 @default.
• W4214653742 hasConceptScore W4214653742C2781148688 @default.
• W4214653742 hasConceptScore W4214653742C2781242345 @default.
• W4214653742 hasConceptScore W4214653742C2781359195 @default.
• W4214653742 hasConceptScore W4214653742C3018023364 @default.
• W4214653742 hasConceptScore W4214653742C71924100 @default.
• W4214653742 hasIssue "7" @default.
• W4214653742 hasLocation W42146537421 @default.
• W4214653742 hasLocation W42146537422 @default.
• W4214653742 hasOpenAccess W4214653742 @default.
• W4214653742 hasPrimaryLocation W42146537421 @default.
• W4214653742 hasRelatedWork W2078285148 @default.
• W4214653742 hasRelatedWork W2079717275 @default.

• next